4.6 Article

a-Glucosidase Inhibitors Based on Oleanolic Acid for the Treatment of Immunometabolic Disorders

Journal

APPLIED SCIENCES-BASEL
Volume 13, Issue 16, Pages -

Publisher

MDPI
DOI: 10.3390/app13169269

Keywords

triterpenoids; oleanolic acid; indole; Mannich reaction; type 2 diabetes; & alpha;-glucosidase inhibiting activity; PTP1B

Ask authors/readers for more resources

A series of new oleanane-type triterpenic derivatives were synthesized from oleanolic acid through various reactions and were evaluated for their potential as treatments for immunometabolic disorders. The compounds showed strong inhibition against a-glucosidase enzyme but had no activity against PTP1B. One particular compound, N-methylpiperazine methylated 2,3-indolo-oleanolic propargyl amide 15, also demonstrated inhibitory effects on NO synthesis and oxidative bursts, making it a promising prototype drug for immunometabolic defects in type 2 diabetes.
Using oleanolic acid as a starting compound, a series of new oleanane-type triterpenic derivatives were synthesized via O-acylation (with nicotinic, isonicotinic, and methoxycinnamic acid acyl chlorides), N-amidation (with cyclic- or polyamines), the Mannich reaction (with secondary cyclic amines), and Claisen-Schmidt condensation (with aromatic aldehydes), and their potencies as treatments for immunometabolic disorders were investigated. The compounds were evaluated against a-glucosidase and PTP1B enzymes and LPS-stimulated murine macrophages. It was found that the target compounds are highly effective a-glucosidase inhibitors but lack activity against PTP1B. A leading compound, N-methylpiperazine methylated 2,3-indolo-oleanolic propargyl amide 15, is also a micromolar inhibitor of NO synthesis in LPS-stimulated macrophages and suppresses oxidative bursts in neutrophils with similar efficiency. These results, in addition to its ability to stimulate glucose uptake in rat fibroblasts and improve maltose tolerance in rats, allow us to consider compound 15 a promising prototype drug for the treatment of immunometabolic defects in type 2 diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available